Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chi-Med Starts US-EU Trials of Oral Lymphoma Drug

publication date: Sep 5, 2019

Hutchison China MediTech (Chi-Med) has started a global Phase I/Ib trial of HMPL-689, the company's oral small molecule phosphoinositide-3 kinase delta isoform (PI3Kδ) inhibitor, enrolling patients with relapsed or refractory lymphoma. Chi-Med dosed the first patient on August 26, 2019 in the US. The lymphoma trial will run in parallel to a similar China Phase I/Ib trial that tests HMPL-689 in a broad range of hematological cancers. Chi-Med says the candidate is highly selective and potent. More details....

Stock Symbol: (AIM/NASDQ: HCM)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here